Optomed Q2: Soft sales and important quarters ahead
Research Update
2024-08-09
07:00
Redeye provides an update following Optomed’s Q2 report. Although sales and EBIT came in lower than anticipated, we argue that the investment case remains intact. We highlight upcoming reports that may potentially show sales related to the US rollout of Aurora AEYE. Furthermore, we have made only minor estimate changes, leaving the fair value range unchanged.
Gustaf Meyer
Analyst Q&A
Closed
Gustaf Meyer answered 2 questions.
Disclosures and disclaimers